The overall aim of the research performed in the network is to gain better control of the HCV epidemic in Egypt.


The specific objectives of this project are:


1) To estimate the magnitude of the epidemic and its morbidity / mortality impact.


2) To identify the risk factors and routes of HCV transmission, as well as high-risk groups, for better prevention programs.


3) To estimate the efficacy of treatment regimens, determine predictors of response to treatment, and elaborate patient management protocols adapted to the local healthcare system.


4) To understand the mechanisms of HCV clearance in acute infection for future drugs and vaccine development.



Given these objectives, the research program has been organised around several study sites (see Figure below): a village cohort in the Nile Delta, four “Fever Hospitals” (Abassia and Imbaba in Cairo, Alexandria Fever Hospital and Assiut Fever Hospital), Ain Shams Hospital, National Treatment Centers and some Health Insurance Organisation hospitals. The figure below shows the project's various study sites (with their main objectives) in relation to which phase of HCV infection the research is focused on.

Sans titre



Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union